Form 4: Replimune Group Chief Medical Officer Sells Shares to Cover Tax Obligations

Konstantinos Xynos, Chief Medical Officer of Replimune Group, sold 7,246 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Konstantinos Xynos, the Chief Medical Officer of Replimune Group, sold 7,246 shares of the company's common stock on November 18, 2024.
• The sale was executed at a price of $10.78 per share.
• This transaction was not a discretionary sale but rather a 'sell to cover' transaction to meet tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Xynos beneficially owns 109,885 shares of Replimune Group common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• The sale of 7,246 shares is not unusual for a company of Replimune's size and stage.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but this is a routine transaction.
• The transaction does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Replimune Group, Konstantinos Xynos, stock sale, Form 4, insider trading, restricted stock units, tax obligations, REPL